{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T21:36:39Z","timestamp":1783460199352,"version":"3.55.0"},"reference-count":23,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2017.0455","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:29:13Z","timestamp":1525253353000},"source":"Crossref","is-referenced-by-count":13,"title":["Methamphetamine-Related Disorders"],"prefix":"10.3238","author":[{"given":"Euphrosyne","family":"Gouzoulis-Mayfrank","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"H\u00e4rtel-Petri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"Hamdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Havemann-Reinecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"M\u00fchlig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Wodarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2017,6,30]]},"reference":[{"key":"10.3238\/arztebl.2017.0455_ref1","unstructured":"Milin S, Lotzin A, Degkwitz P, et al.: Amphetamin und Methamphetamin \u2013 Personengruppen mit missbr\u00e4uchlichem Konsum und Ansatzpunkte f\u00fcr pr\u00e4ventive Ma\u00dfnahmen. Sachbericht. 2014. www.methstudie.de\/ats-bericht.pdf (last accessed 2 June 2017)."},{"key":"10.3238\/arztebl.2017.0455_ref2","unstructured":"Die Drogenbeauftragte der Bundesregierung, Bundesministerium f\u00fcr Gesundheit (BMG), Bundes\u00e4rztekammer (B\u00c4K), Deutsche Gesellschaft f\u00fcr Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN): S3-Leitlinie Methamphetamin-bezogene St\u00f6rungen. Leitlinienreport. 1st Edition. Version 1. doi.org\/10.6101\/AZQ\/000337 (last accessed on 21 November 2016)."},{"key":"10.3238\/arztebl.2017.0455_ref3","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF): Das AWMF-Regelwerk Leitlinien. M\u00fcnchen: Zuckschwerdt 2012."},{"key":"10.3238\/arztebl.2017.0455_ref4","unstructured":"Guidelines Development Working Party, Jenner J, Spain D, et al.: Management of patients with psychostimulant toxicity: guidelines for emergency departments. Canberra: Australian Government Department of Health and Ageing 2006."},{"key":"10.3238\/arztebl.2017.0455_ref5","unstructured":"Turning Point Alcohol and Drug Centre, Lee N, Johns L, et al.: No 14: Methamphetamine dependence and treatment. Fitzroy, Victoria: Turning Point Alcohol and Drug Centre 2007."},{"key":"10.3238\/arztebl.2017.0455_ref6","doi-asserted-by":"crossref","unstructured":"Shoptaw S, Huber A, Peck J, et al.: Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend 2006; 85: 12\u20138","DOI":"10.1016\/j.drugalcdep.2006.03.005"},{"key":"10.3238\/arztebl.2017.0455_ref7","doi-asserted-by":"crossref","unstructured":"Rawson RA, Marinelli-Casey P, Anglin MD, et al.: A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction 2004; 99: 708\u201317","DOI":"10.1111\/j.1360-0443.2004.00707.x"},{"key":"10.3238\/arztebl.2017.0455_ref8","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA): Counselor\u2018s treatment manual: matrix intensive outpatient treatment for people with stimulant use disorders. Reprinted 2007. Rockville, MD: SAMHSA 2006."},{"key":"10.3238\/arztebl.2017.0455_ref9","doi-asserted-by":"crossref","unstructured":"Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J: Pharmacotherapy of methamphetamine addiction: an update. Subst Abus 2008; 29: 31\u201349","DOI":"10.1080\/08897070802218554"},{"key":"10.3238\/arztebl.2017.0455_ref10","doi-asserted-by":"crossref","unstructured":"McCann DJ, Li SH: A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. CNS Neurosci Ther 2012; 18: 414\u20138","DOI":"10.1111\/j.1755-5949.2011.00263.x"},{"key":"10.3238\/arztebl.2017.0455_ref11","doi-asserted-by":"crossref","unstructured":"Anderson AL, Li SH, Markova D, et al.: Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2015; 150: 170\u20134","DOI":"10.1016\/j.drugalcdep.2015.01.036"},{"key":"10.3238\/arztebl.2017.0455_ref12","doi-asserted-by":"crossref","unstructured":"Galloway GP, Newmeyer J, Knapp T, Stalcup SA, Smith D: Imipramine for the treatment of cocaine and methamphetamine dependence. J Addict Dis 1994; 13: 201\u201316","DOI":"10.1300\/J069v13n04_08"},{"key":"10.3238\/arztebl.2017.0455_ref13","doi-asserted-by":"crossref","unstructured":"Galloway GP, Newmeyer J, Knapp T, Stalcup SA, Smith D: A controlled trial of imipramine for the treatment of methamphetamine dependence. J Subst Abuse Treat 1996; 13: 493\u20137","DOI":"10.1016\/S0740-5472(96)00154-7"},{"key":"10.3238\/arztebl.2017.0455_ref14","doi-asserted-by":"crossref","unstructured":"Anderson AL, Li SH, Biswas K, et al.: Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend 2012; 120: 135\u201341","DOI":"10.1016\/j.drugalcdep.2011.07.007"},{"key":"10.3238\/arztebl.2017.0455_ref15","doi-asserted-by":"crossref","unstructured":"Ling W, Shoptaw S, Hillhouse M, et al.: Double-blind placebo-controlled evaluation of the PROMETA protocol for methamphetamine dependence. Addiction 2012; 107: 361\u20139","DOI":"10.1111\/j.1360-0443.2011.03619.x"},{"key":"10.3238\/arztebl.2017.0455_ref16","doi-asserted-by":"crossref","unstructured":"Wang T, Shen B, Shi Y, Xiang P, Yu Z: Chiral separation and determination of R\/S-methamphetamine and its metabolite R\/S-amphetamine in urine using LC-MS\/MS. Forensic Sci Int 2015; 246: 72\u20138","DOI":"10.1016\/j.forsciint.2014.11.009"},{"key":"10.3238\/arztebl.2017.0455_ref17","doi-asserted-by":"crossref","unstructured":"Rawson RA, Chudzynski J, Gonzales R, et al.: The impact of exercise on depression and anxiety symptoms among abstinent methamphetamine-dependent individuals in a residential treatment setting. J Subst Abuse Treat 2015; 57: 36\u201340","DOI":"10.1016\/j.jsat.2015.04.007"},{"key":"10.3238\/arztebl.2017.0455_ref18","doi-asserted-by":"crossref","unstructured":"Dolezal BA, Chudzynski J, Storer TW, et al.: Eight weeks of exercise training improves fitness measures in methamphetamine-dependent individuals in residential treatment. J Addict Med 2013; 7: 122\u20138","DOI":"10.1097\/ADM.0b013e318282475e"},{"key":"10.3238\/arztebl.2017.0455_ref19","doi-asserted-by":"crossref","unstructured":"Rostami R, Dehghani-Arani F: Neurofeedback training as a new method in treatment of crystal methamphetamine dependent patients: a preliminary study. Appl Psychophysiol Biofeedback 2015; 40: 151\u201361","DOI":"10.1007\/s10484-015-9281-1"},{"key":"10.3238\/arztebl.2017.0455_ref20","doi-asserted-by":"crossref","unstructured":"Nejtek VA, Avila M, Chen LA, et al.: Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized double-blind trial. J Clin Psychiatry 2008; 69: 1257\u201366","DOI":"10.4088\/JCP.v69n0808"},{"key":"10.3238\/arztebl.2017.0455_ref21","doi-asserted-by":"crossref","unstructured":"Brown ES, Gabrielson B: A randomized, double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence. J Affect Disord 2012; 143: 257\u201360","DOI":"10.1016\/j.jad.2012.05.006"},{"key":"10.3238\/arztebl.2017.0455_ref22","doi-asserted-by":"crossref","unstructured":"Hellem TL, Lundberg KJ, Renshaw PF: A review of treatment options for co-occurring methamphetamine use disorders and depression. J Addict Nurs 2015; 26: 14\u201323","DOI":"10.1097\/JAN.0000000000000058"},{"key":"10.3238\/arztebl.2017.0455_ref23","doi-asserted-by":"crossref","unstructured":"Sherman SG, Sutcliffe C, Srirojn B, Latkin CA, Aramratanna A, Celentano DD: Evaluation of a peer network intervention trial among young methamphetamine users in Chiang Mai, Thailand. Soc Sci Med 2009; 68: 69\u201379","DOI":"10.1016\/j.socscimed.2008.09.061"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2017.0455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T10:27:59Z","timestamp":1638872879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2017.0455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,30]]},"references-count":23,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2017.0455","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,30]]}}}